CIPLA
|
The Current P/E Ratio of CIPLA is 32.95.
| Share Price | ₹1,372.3 | Sep 17,2026 |
| Market Cap | ₹110,864.1 Cr | |
| Earnings-TTM | ₹3,364.8 Cr | TTM-Consolidated Results |
| Price/Earnings | 32.95x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CIPLA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹110,864.1 Cr] as on Sep 17,2026
(/) Earnings [ ₹3,364.8 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 32.95x ]
Thus, for CIPLA , the investors are currently willing to pay 32.95 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CIPLA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CIPLA over the last five years.
Historical PE (Price/Earnings) ratio chart of CIPLA
PE Ratio Performance Analysis for CIPLA
- CIPLA 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 27.09x.
- CIPLA 's operated at median p/e ratio of 25.95x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CIPLA 's p/e ratio peaked in Mar2022 at 32.65x.
- CIPLA 's p/e ratio hit its five-year low in Mar2025 of 22.08x.
How does CIPLA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CIPLA | 3,364.84 | 32.95 | 110,864.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 36.78 | 447,716.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 84.83 | 248,120.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 86.29 | 186,038.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.87 | 97,828.7 |
| MANKIND PHARMA LTD | 2,055.11 | 46.13 | 94,793.9 |
| LUPIN LTD | 5,551.01 | 17.23 | 95,660.0 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.26 | 113,451.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.10 | 96,890.8 |
| LAURUS LABS LTD | 1,090.76 | 96.91 | 105,707.0 |
| BIOCON LTD | 416.40 | 148.72 | 61,928.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CIPLA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.23x |
| Max industry PE | 148.72x |
| Median industry PE | 36.78x |
| Average industry PE | 57.46x |
You may also like the below Video Courses